Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015

• DOI: 10.6004/jnccn.2016.0018
• Publication Date: 2017-04-14T16:07:51Z
• Authors: Mary B. Daly; Robert Pilarski; Jennifer E. Axilbund; Michael Berry; Saundra S. Buys; Beth Crawford; Meagan Farmer; Susan Friedman; Judy E. Garber; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison Kurian; Jennifer K. Litton; Lisa Madlensky; P. Kelly Marcom; Sofia D. Merajver; Kenneth Offit; Tuya Pal; Huma Rana; Gwen Reiser; Mark E. Robson; Kristen Mahoney S...; Elizabeth Swisher; Nicoleta C. Voian; Jeffrey N. Weitzel; Alison Whelan; Myra J. Wick; Georgia L. Wiesner; Mary Dwyer; Rashmi Kumar; Susan Darlow
• Keywords: Ovarian Neoplasms; Breast Neoplasms; Genetic Counseling; Risk Assessment; 3. Good health; Pancreatic Neoplasms; 03 medical and health sciences; 0302 clinical medicine; Neoplastic Syndromes, Hereditary; Risk Factors; Mutation; Humans; Female; Genetic Predisposition to Disease; Genetic Testing

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer and are intended to assist with clinical and shared decision-making. These NCCN Guidelines Insights summarize major discussion points of the 2015 NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meeting. Major discussion topics this year included multigene testing, risk management recommendations for less common genetic mutations, and salpingectomy for ovarian cancer risk reduction. The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer.